Scholars@Duke
James Emmett Herndon II

James Emmett Herndon II

Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
james.herndon@duke.edu
Duke Box 2717, Durham, NC 27710
2424 Erwin Road, 8020 Hock Plaza, Durham, NC 27705

Overview

Current research interests have application to the design and analysis of cancer clinical trials. Specifically, interests include the use of time-dependent covariables within survival models, the design of phase II cancer clinical trials which minimize some of the logistical problems associated with their conduct, and the analysis of longitudinal studies with informative censoring (in particular, quality of life studies of patients with advanced cancer).

Current Appointments & Affiliations

Professor of Biostatistics & Bioinformatics · 2022 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics
Member of the Duke Cancer Institute · 1988 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications

Perioperative Depressive Symptoms in Surgical Cancer Patients: a Systematic Review and Meta-analysis.

Journal Article Ann Surg Oncol · January 6, 2026 BACKGROUND: Patients with cancer requiring surgery are at increased risk for depressive symptoms. However, prevalence and severity during the perioperative period are poorly characterized. This study systematically reviewed the perioperative prevalence of ... Full text Link to item Cite

Clinical trial of feasibility for mindfulness intervention for patients with newly diagnosed high grade glioma.

Journal Article J Neurooncol · November 5, 2025 PURPOSE: With a bleak prognosis for malignant glioma, maintaining quality of life (QoL) and decreasing distress are essential in patient clinical care. Mindfulness meditation is a mind-body therapy that is being investigated as a non-pharmacological strate ... Full text Link to item Cite

A Phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer.

Journal Article Cancer · November 1, 2025 BACKGROUND: Treatment options for patients with advanced non-small cell lung cancer (NSCLC) with disease progression following immune checkpoint inhibitor (ICI) and platinum-based chemotherapy are limited. GT103 is a fully human immunoglobulin G3 monoclona ... Full text Link to item Cite
View All Publications

Recent Grants

Inflammasomes - a driver of sexual dimorphism to glioma therapies

ResearchCo Investigator · Awarded by National Institutes of Health · 2025 - 2030

McCain/Bayh Glioblastoma Consortium

Clinical TrialCo Investigator · Awarded by Department of Defense · 2025 - 2029

Comparison of convection enhanced delivery systems in a clinical study of recurrent Grade 3-4 glioma patients

ResearchBiostatistician Investigator · Awarded by CreoSalus · 2025 - 2027

View All Grants

Education, Training & Certifications

University of North Carolina, Chapel Hill · 1988 Ph.D.